Louis, E, Resche-Rigon, M, Laharie, D, et al. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 8 (2023), 215–227.
Baert, F, Noman, M, Vermeire, S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003), 601–608.
Louis, E, Mary, J-Y, Vernier-Massouille, G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142 (2012), 63–70.
Farrell, RJ, Alsahli, L, Jeen, YT, Falchuk, KR, Peppercorn, MA, Michetti, P, Hydrocortisone intravenous pre-medication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003), 917–924.
